Andere talen IMV Corporation

Aandelen

7760

JP3100760002

Vertraagde tijd Japan Exchange Andere beurzen 04:30:00 13-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
660 ^JPY	+8,55%		+2,64%	+26,68%

25/03	BioVaxys Technology plant onderhandse plaatsing; 5,9% lager	MT
2023	IMV Corporation (TSE:7760) kondigt een aandeleninkoop aan voor 400.000 aandelen, die 2,45% vertegenwoordigen voor ¥250 miljoen.	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Tranche Update on IMV Corporation's Equity Buyback Plan announced on November 21, 2023.	09/04
BioVaxys Technology Plans Private Placement; Down 5.9%	25/03
Biovaxys Completes The Acquisition Of All Intellectual Property And Clinical Stage Assets Of The Former IMV Inc.	21/02
BioVaxys Acquires Entire Technology Portfolio Of The Former IMV Inc.	12/02
Tranche Update on IMV Corporation's Equity Buyback Plan announced on November 21, 2023.	15/01
IMV Corporation announces an Equity Buyback for 400,000 shares, representing 2.45% for ¥250 million.	21/11
IMV Corporation authorizes a Buyback Plan.	21/11
IMV Corporation Reports Earnings Results for the Full Year Ended September 30, 2023	10/11
EKF Diagnostics hires CFO from Trellus Health, latter names successor	12-09-23
Trellus Health's Interim Finance Head Takes Full-time CFO Role at EKF Diagnostics	12-09-23
Imv Corporation Provides Dividend Guidance for the Fiscal Year Ending September 30, 2023	09-06-23
Imv Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending September 30, 2023	09-06-23
IMV Corporation Reports Earnings Results for the Half Year Ended March 31, 2023	12-05-23
IMV Receives Delisting Notice From Nasdaq Over Bankruptcy Proceedings in Canada	09-05-23
IMV Inc. Brief: Says Received NASDAQ Delisting Notice	08-05-23
IMV Inc. Brief: Says Received Nasdaq Notification Regarding Minimum Bid Price Deficiency	31-03-23
IMV Inc. Details Board Changes	27-03-23
IMV Inc. Brief: Hall Adds Co engaged Stonegate to explore strategic alternatives, "So that MVP-S can realize its full clinical potential"	16-03-23
IMV Inc. Brief: Andrew Hall, Chief Executive Officer, Said" "The market headwinds limiting available capital are, however, very real"	16-03-23
IMV Inc. Brief: Net loss and comprehensive loss of US$38.0 million ($4.55 per share) for Year ended December 31, 2022, Vs net loss and comprehensive loss of $36.6 ($4.93 per share) for Year ended December 31, 2021	16-03-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen IMV Corporation

Aandelen

7760

JP3100760002

Andere talen

Filters